395 related articles for article (PubMed ID: 23393196)
21. Next-generation oncolytic vaccinia vectors.
Thorne SH
Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
[TBL] [Abstract][Full Text] [Related]
22. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ; Thorne SH; Bell JC; Kirn DH
Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
24. Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma.
Kung CH; Kuo SC; Chen TL; Weng WS
BMC Cancer; 2015 Oct; 15():704. PubMed ID: 26471278
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
26. Synergistic antitumor effects of immune cell-viral biotherapy.
Thorne SH; Negrin RS; Contag CH
Science; 2006 Mar; 311(5768):1780-4. PubMed ID: 16556847
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma.
Ady JW; Johnsen C; Mojica K; Heffner J; Love D; Pugalenthi A; Belin LJ; Chen NG; Yu YA; Szalay AA; Fong Y
Surgery; 2015 Aug; 158(2):331-8. PubMed ID: 26049609
[TBL] [Abstract][Full Text] [Related]
29. Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines.
Lee HJ; Rho J; Gui SR; Kim MK; Lee YK; Lee YS; Kim JE; Cho E; Cho M; Hwang TH
Korean J Hepatol; 2011 Sep; 17(3):213-9. PubMed ID: 22102388
[TBL] [Abstract][Full Text] [Related]
30. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
[TBL] [Abstract][Full Text] [Related]
32. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
33. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Tsujinoue H; Imazu H; Fukui H
Int J Oncol; 2002 Jun; 20(6):1227-31. PubMed ID: 12012003
[TBL] [Abstract][Full Text] [Related]
34. Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
Wang J; Arulanandam R; Wassenaar R; Falls T; Petryk J; Paget J; Garson K; Cemeus C; Vanderhyden BC; Wells RG; Bell JC; Le Boeuf F
J Nucl Med; 2017 Feb; 58(2):221-227. PubMed ID: 27635026
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
Hou W; Chen H; Rojas J; Sampath P; Thorne SH
Int J Cancer; 2014 Sep; 135(5):1238-46. PubMed ID: 24474587
[TBL] [Abstract][Full Text] [Related]
36. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
Gholami S; Marano A; Chen NG; Aguilar RJ; Frentzen A; Chen CH; Lou E; Fujisawa S; Eveno C; Belin L; Zanzonico P; Szalay A; Fong Y
Breast Cancer Res Treat; 2014 Dec; 148(3):489-99. PubMed ID: 25391896
[TBL] [Abstract][Full Text] [Related]
37. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
Kim JH; Oh JY; Park BH; Lee DE; Kim JS; Park HE; Roh MS; Je JE; Yoon JH; Thorne SH; Kirn D; Hwang TH
Mol Ther; 2006 Sep; 14(3):361-70. PubMed ID: 16905462
[TBL] [Abstract][Full Text] [Related]
38. Exploring the role of oncolytic viruses in hepatobiliary cancers.
Tenneti P; Borad MJ; Babiker HM
Immunotherapy; 2018 Aug; 10(11):971-986. PubMed ID: 29900755
[TBL] [Abstract][Full Text] [Related]
39. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.
Weibel S; Raab V; Yu YA; Worschech A; Wang E; Marincola FM; Szalay AA
BMC Cancer; 2011 Feb; 11():68. PubMed ID: 21320309
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
